ÔÇ∑ÔÇ∑
‚Ä¢Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal
information, or to otherwise protect the integrity
 of the clinical study.Title: An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-
Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic 
Stem Cell Transplantation (HSCT)
Study ID: [REMOVED]
SAP Approve Date: June 04, 2018
Certain information  within this Statistical Analysis Plan has been r edacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable ([COMPANY_003]) information 
or company confidential information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Vedolizumab-1015 Page 1 of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
STATISTICAL ANALYSIS PLAN
STUDY NUMBER: Vedolizumab-[ADDRESS_810789] Disease (GvHD) Prophylaxis in 
Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
PHASE 1b
Version : Final v1.0
Date :June 04, 2018
Prepared by:
[CONTACT_490570]:
Protocol Version: 2.0
Protocol Date: December 22, 2016
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of [COMPANY_005]. Acceptance of this document 
constitutes the agreement by [CONTACT_1955][INVESTIGATOR_63147].[COMPANY_003]
Vedolizumab -1015 Page 2of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL1.1 Approval Signatures
Study Title: An Open -Label, Dose -Finding Study  of Vedolizumab IV for Treatment of 
Steroi d-Refractory  Acute Intestinal Graft -Versus -Host Di sease (GvHD) 
Prophylaxis in Pat ients Undergoing Allogeneic Hematopoiet ic Stem Cell 
Transplantation (HSCT)
Approvals: Electroni c signatures can be found on the last page of this document.
Vedolizumab -[ADDRESS_810790] ics..................................................... 19
7.6 Medicat ion History  and Concomi tant Medi cations................................................... 21
7.7 Study  Drug Exposure and Compliance ..................................................................... 21
7.8 Efficac y Analyses .................................................................................................... 21
7.8.1 Primary Efficacy  Endpoint ................................................................................. 21
7.8.2 Secondary  Efficacy  Endpoints ............................................................................ 21
7.8.3 Exploratory  Efficacy  Endpoints ......................................................................... 22
7.8.4 Descript ive Summary of Efficacy Endpo ints...................................................... 23
Vedolizumab -1015 Page 4of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL7.9 Pharmacoki netic/Pharmacodynamic Analysis .......................................................... [ADDRESS_810791] OF IN -TEXT TABLES
Table 5.a Descript ion of the Primary  Endpoints .................................................................11
Table 5.b Descript ion of the Secondary  Endpo ints............................................................. 11
Table 5.c Descript ion of the Exploratory  Endpo ints........................................................... 12
Table 7.a Visit Wind ows to be used for the summary  of the efficacy  endpoints. ................ 15
Table 7.b Visit Windows to be used for the summary  of the PD and bio marker 
endpo ints........................................................................................................... 16
Table 7.c. Summary  of Patients' Baseline and Demographic Characteristics ....................... [ADDRESS_810792] OF IN -TEXT FIGURES
Figure 4.a Overview of Study  Design (from  day -1 to +50) ................................................... [ADDRESS_810793] allogeneic hematopoietic stem cell transplantation
AML acute my eloid leukemia
ANC absolute neutrophil c ount
APC antigen -presenting cell
AUC area under the serum concentration -time curve
AVA anti-vedolizumab antibody
BMT CTN Blood and Marrow Transplant Clinical Trials Network 
BuFlu busulfan + fludaradine
Ctrough serum concentration before dosing
CMV cytomegalovirus
CRF case report form
CRO contract research organization
CRp complete remission with incomplete platelet recovery
CTCAE Common Terminology Criteria for Adverse Events 
CyTBI cyclophosphamide + total body irradiation
DLT dose-limiting t oxicity
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EU European Union
FDA Food and Drug Administration
GALT gut-associated lymphoid tissue 
GCP Good Clinical Practice
GCSF granulocyte -colon y stimulating factor
GI gastro intestinal(ly)
GRFS GvHD -free, relapse -free survival
GvHD graft -versus -host disease
HBV hepatitis B virus surface antigen
HCT -CI Hematopoietic Cell Transplantation -Specific Comorbidity Index
HCV hepatitis C virus antigen
HIV human immunodeficiency vi rus
HLA human leukocyte antigen
HSC hematopoietic stem cell
HSCT hematopoietic stem cell transplantation
IAC Independent Adjudication Committee 
IB Investigator‚Äôs Brochure
IBD inflammatory bowel disease
IBMTR International Bone Marrow Transplant Reg istry Database
Vedolizumab -[ADDRESS_810794]
IV intravenous(ly)
MAdCAM -[ADDRESS_810795] level
OS overall survival
PCR polymerase chain reaction
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PML progressive multifocal leukoencephalopathy
PTE pretreatment event
PVC polyvinyl chloride
Q4W once ever y [ADDRESS_810796] ical analysis plan
ST2 suppressor of tumorigenicity 2
TB tuberculosis
TEAE treatment -emergent adverse event
US [LOCATION_002]
WHO World Health Organization
Vedolizumab-1015 Page 7 of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL4.0 OBJECTIVES
4.1 Primary Objectives
The primary objective is:
!To describe the initial tolerability and safety and identify a recommended phase [ADDRESS_810797] GvHD 
prophylaxis therapy (tacrolimus plus short-term methotrexate) in patients undergoing 
allo-HSCT.
4.2 Secondary Objectives
The secondary objectives are:
!To characterize the PK of vedolizumab in patients on Days -1, +13 and +[ADDRESS_810798].
!To determine the cumulative incidence and severity of acute GvHD (compi[INVESTIGATOR_611472], skin, or liver) at [ADDRESS_810799].
!To determine the distribution of maximum severity of acute GvHD throughout the 
100-day period after allo-HSCT.
4.3 Exploratory Objectives
The exploratory objectives are:
CCI
Vedolizumab-[ADDRESS_810800] disease (GvHD) 
prophylaxis (tacrolimus plus short-term methotrexate) in adult patients (18‚Äî75 years old) 
undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab dose 
finding will be cohort based and follow a rule-based dose-finding study design with 
pharmacokinetic (PK) guidance. After a tolerated dose with acceptable PK has been identified, 
the cohort at that dose level may be expanded to further assess the tolerability and effectiveness 
of vedolizumab. 
Eligibility will be determined during the Screening period, which may last for up to 28 days 
before Day ‚Äì1 (designation of the day of the fi rst IV infusion of vedolizumab). Patients who  
meet all eligibility criteria and provide written informed consent will be enrolled in this study. 
Vedolizumab will be administered initially on Day ‚Äì[ADDRESS_810801] and then on Days +13 
and +[ADDRESS_810802] or until the patient‚Äôs death or withdrawal of consent or 
termination of the study by [CONTACT_456]. All patients will be followed for overall survival (OS) 
until death, withdrawal of consent, termination of the study by [CONTACT_456], or for a maximum of 
[ADDRESS_810803] patient is enrolled in the study. Patients will attend a Day +100 visit (¬±7 
days) at which time they will enter post treatment follow-up. 
Dose escalation will start with a low-dose cohort receiving vedolizumab at 75 mg IV on Day ‚Äì1 
and on Days +13 and +[ADDRESS_810804]. HSC infusion should occur on Day 0 (no sooner than 
12 hours after completion of IV infusion of vedo lizumab on Day ‚Äì1). The first patient in each 
dosing cohort will then be monitored for dose- limiting toxicities (DLTs) from the start of the 
first IV infusion of vedolizumab on Day ‚Äì1 to Day +[ADDRESS_810805] (the DLT observation 
period) including assessment for neutrophil recovery by [CONTACT_2006] +28. If the first patient in the first CCI
Vedolizumab -[ADDRESS_810806] 3 patients experience DLTs, the next cohort will 
receive vedo lizumab 300 mg IV on Day ‚Äì1 and on Day s +13 and +[ADDRESS_810807] 3 patients in the 
cohort experiences a DLT, then 3 additional pat ients will be enro lled at the same dose level and 
monitored for DLTs from Day  ‚Äì1 until  Day +28. If none of the addit ional pat ients experi ence a 
DLT, then the decisio n on whether to increase the vedo lizumab IV dose in the next cohort will 
be guided by [CONTACT_611477]. If 2 or more patients in a cohort of eithe r 3 or 6 pati ents experience 
a DLT, then the dose of vedo lizumab IV for the next cohort of 3 patients will be reduced. These 
patients will  be monitored f or DLTs in the same manner that patients in the previous cohort were 
monitored. DLT will be considered as a part of the PK/PD analysis and will be further outlined 
in the Clinical Pharmaco logy Analysis Plan (CPAP).
The graphical study  design is presented on Figure 4.a.
Figure 4.a Overview of Study Design (from day - 1 to +50)
Allo-HSCT=allogeneic hematopoietic stem cell transplantation, AVA=anti -vedolizumab antibodies, 
DLT=dose -limiting toxicity , GvHD=graft -versus -host disease, IV=intravenous, PK=pharmacokinetic.
PK sampling for patients who have been discharged from the hospi[INVESTIGATOR_611473], and 
therefore may not be as frequent as represented in this figure. 
After a tol erated dose level wit h acceptable PK has been ident ified in pat ients who are 
undergo ing un related -donor myeloablat ive transplant for the treatment of hematologic 
Vedolizumab -1015 Page 10of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALmalignancies, the coh ort at that dose level may be expanded to include approximately  18 
additional patients undergoing myeloablat ive condit ioning or reduced- intensit y condit ioning 
(RIC ) and are receiving eit her rel ated or unrelated allo -HSCT for the treatment of hematologic 
malignancies or myelopro liferat ive neopl asms. This group of patients will allo w the further 
assessment of the tolerabilit y and clinical act ivity of vedo lizumab IV.
Vital signs, physical and neurological examinations, adverse event (AE) assessments, and 
laboratory  values (chemistry , hematol ogy, and urinalysis) will be obtained to evaluate the safet y 
and tol erabilit y of vedo lizumab IV. To exclude patients with progressi ve multifocal 
leukoencephalopathy  (PML), a Risk Assessment and Minimizat ion for PML (RAMP) 
questionnaire will be administered at Screening and before vedo lizumab IV administration on 
Days -[ADDRESS_810808], and on Days +13 and +[ADDRESS_810809] GvHD prophylaxis therapy are listed in 
Table 5.a:
Table 5.a Description of the Primary Endpoint s
Type of the Endpoints Description of the Endpoints
Primary Safety Endpoints Frequency of DLTs from the start of the first IV infusion of vedolizumab on 
Day ‚Äì1 until Day +2 8 (the DLT observation period).
The number and percentage of patients who experience treatment -emer gent 
adverse events (TEAEs) from administration of the first dose of vedolizumab 
IV thr ough [ADDRESS_810810] dose of vedolizumab I V.
The number and percentage of patients who experience serious adverse 
events (SAEs) from administration of the first dose of vedolizumab IV 
through [ADDRESS_810811].
5.2 Secondary Endpoints
The secondary  endpoints are listed in Table 5.b:
Table 5.b Description of the Secondary Endpoints
Type of the Endpoints Description of the Endpoints
Secondary Efficacy 
EndpointsTime to neutrophil engraftment .
Percentage of patients who have developed overall Grade 2 to 4 acute GvHD (compi[INVESTIGATOR_611472], skin, or liver) by [ADDRESS_810812](see GvHD assessment schedule in 
Appendix C), defined according to the modified Glucksberg criteria and Blood and Marrow 
Transplant Clinical Trials Network (BMT CTN) -modified International Bone Marrow 
Transplant Registry Database (IBMTR) index (See Appendix D).
Secondary PK Endpoint Mean serum concentrations of vedolizumab before dosing (Ctrough) on Days +13 and +[ADDRESS_810813].
Vedolizumab-1015 Page 12 of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL5.3 Exploratory Endpoints
The exploratory endpoints are listed in  Table 5.c:
Table 5.c Description of the Exploratory Endpoints.
CCI
Vedolizumab -[ADDRESS_810814] GvHD prophylaxis.
Vedolizumab -1015 Page 14of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL7.0 METHODS OF ANALYSIS AND PRESENTATION
7.1 General Principles 
Statistical analysis plan (SAP) will be prepared and finalized prior to database freeze . After 
cleaning the data,the analyses of theprimary, secondary and exploratory  endpoints will be 
perform ed.Additional analysis will be performed after the [ADDRESS_810815] data 
management operating procedures.
7.2 Study Definitions and Conventions
7.2.1 Study Terms
The definit ions of the study  term s are provi ded in the table below:
Term Definition
Clinical Remission
(for overall design 
and escalation phase
entry)Defined by [CONTACT_611478]: <5% blast cells, count recovery 
(although complete remission with incomplete platelet recovery [CRp] would 
be allowed), and no evidence of extramedullary disease.
Clinical Remission
(for expansion phase)Defined for patients with one of the following criteria :
a)Acute leukemia, chronic myelogenous leukemia, and myelodysplasia with 
no circulating blasts an d <5% blasts in the bone marrow; OR
b)  Chronic lymphocytic leukemia, small lymphocytic lymphoma, or other 
non-Hodgkin lymphoma with chemosensitive dis ease at time of 
transplantation; OR
c)Myelofibrosis and other myeloproliferative neoplasms with <5% blasts in 
the blood and bone marrow.
Acute GvHD Defined as clinical evidence of acute GvHD per Glucksber g and IBMTR
Chronic GvHD Defined as clinical evidence of chronic GvHD by [CONTACT_611479] [ANC], defined by [CONTACT_217779] >500/mm3
for 3 consecutive days or >2000/m m3for [ADDRESS_810816] day of the 3- day 
period will be considered the day of neutrophil engraftment.
Overall Survival
(OS)Defined as the time from the date of enrollment to the date of death. Patients 
without documentation of death at the time of analys is will be censored at the 
date last known to be alive.
GRFS Defined as Grade 3 ‚Äî4 acute GvHD, chronic GvHD requiring systemic 
immunosuppression, disease relapse or progression, or death due to any cause.
Vedolizumab -1015 Page 15of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL7.2.2 Definition of Study Days
Study  Day  0is defined as the date on which HSC infusio n occurs (no sooner than 12 hours after 
completion of IV infusio n of vedo lizumab on Day ‚Äì1). Other study days are defined relat ive to 
the Study  Day 0with Day  +[ADDRESS_810817] dose 
of study  drug (Study  Day -1). All data will be categori zed based on the scheduled and actual 
sampling t ime at which it w as collected , allowing equally distanced windows (See Table 7.a) 
between the scheduled days when applicable. Thevisit windows should be used to summarize 
theendpo ints that are defined to target the scheduled visit day s.
Table 7.a Visit Windows to be used for the summary of the efficacy endpoints .
Scheduled 
Visit DayAssessment of 
GvHDSymptom -directed 
physical examinationVital signs Weight
Screening ‚â§-2 ‚â§-2
-1 -1 -1 (b)
[ADDRESS_810818] (no sooner than 12 hours after IV vedolizumab infusion)
+1 Blood sample collection (within 24 ¬±[ADDRESS_810819] -dose from Day 0)
+7¬±2 +1 ‚Äî+10 +1‚Äî+10 +1‚Äî+10 +1‚Äî+10
+13¬±2 +11 ‚Äî+16 +11 ‚Äî+16 +11‚Äî+16(b)+11 ‚Äî+16
+20¬±2 +17 ‚Äî+23 +17‚Äî+23 +17‚Äî+23 +17‚Äî+23
+26¬±2 +24 ‚Äî+30 +24 ‚Äî+30 +24 ‚Äî+30 +24 ‚Äî+30
+34¬±2 +31 ‚Äî+38 +31 ‚Äî+38 +31 ‚Äî+38 +31 ‚Äî+38
+42¬±2 +39 ‚Äî+71 +39 ‚Äî+71 +39 ‚Äî+71(b)+39 ‚Äî+71
+100 ¬±7 +72 ‚Äî+110 +72 ‚Äî+110 +72 ‚Äî+110 +72 ‚Äî[PHONE_12654] mo nth(a)
follow up+111 ‚Äî+135 +111 ‚Äî+135 +111 ‚Äî+135 +111 ‚Äî[PHONE_12655] mo nth(a)
follow up+136 ‚Äî+165  +136 ‚Äî+165 +136 ‚Äî+165 +136 ‚Äî+165 
6 mo nth(a)
follow up+166 ‚Äî+225 +166 ‚Äî+225 +166 ‚Äî+225 +166 ‚Äî[PHONE_12656] mo nth(a)
follow up+226 ‚Äî+315 +226 ‚Äî+315 +226 ‚Äî+315 +226 ‚Äî[PHONE_12657] month(a)
follow up‚â•+316 ‚â•+316 ‚â•+316 ‚â•+316
(a) One month here is considered to be 30 days. (b) Vital signs will be obtained before and within 60 minutes o f 
completion of IV infusion of v edolizumab . 
Vedolizumab -1015 Page 16of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALTable 7.b Visit Wind ows to be used for the summary of the PD and biomarker 
endpoints.
Scheduled Visit Day Flow Cytometry Biomarkers
Screening
-1 ‚â§-1 ‚â§-[ADDRESS_810820] (no sooner than 12 hours after IV vedolizumab infusion)
+1 +1 ‚Äî+3 +1 ‚Äî+3
+7¬±2 +4‚Äî+10 +4‚Äî+10
+13¬±2 +11 ‚Äî+16 +11 ‚Äî+16
+20¬±2 +17 ‚Äî+23 +17 ‚Äî+23
+26¬±2 +24 ‚Äî+30 +24 ‚Äî+30
+34¬±2 +31 ‚Äî+38 +31 ‚Äî+38
+42¬±2 +39‚Äî+111 +39‚Äî+71
+100 ¬±7 NA ‚â•+72 
6 mo nth(a)follow up +112 ‚Äî+270 NA
12 month(a)follow up ‚â•+271 NA
(a)One month here is considered to be [ADDRESS_810821] dose of study  drug (or from signing of the informed consent in 
case of SAE) through [ADDRESS_810822] dose of study  drug , and shoul d be summarized 
based on the reported dates (not following windows).
Subjects disposit ion tables should be based on the reported dates (not fo llowing visit windows).
7.2.[ADDRESS_810823] igator.
For AEs or SAEs, a missing or incomplete onset date will be imputed according to the fo llowing 
convent ions:
1)If an onset date is missing, the derived onset date will be calculated as the first non -
missing valid date from the fo llowing list (in order of precedence):
oFirst study  medicat ion date
oConsent date (for SAEs only)
2)If an onset date is inco mplete, the derived onset date will be calculated f ollowing:
Vedolizumab -1015 Page 17of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALoMissing day , but m onth and y ear present: the day  will be imputed as the 15thof 
the month. If the first study  medicat ion dose occurs after the imputed date, the 
derived onset date will be set equal to the first study medicat ion date. 
oMissing da y and m onth, but y ear present: the day  and m onth will  be imputed as 
the 30thJune of the y ear. If the first study  medicat ion dose occurs after the 
imputed date, the derived onset date will be set equal to th e first study  medicat ion 
date.
For AEs or SAEs, a missing or incomplete end date will be imputed according to the fo llowing 
convent ions:
1) If an end date is missing, the derived end date will be imputed the last assessment date. 
2)If an end date is inco mplete, the derived end date will be calculated fo llowing:
oMissing day , but m onth and y ear present: the day  will be imputed as the last date 
(for example February  2009 will be imputed as 28 February  2009) of the m onth.   
oMissing day  and m onth, but y ear present: the day  and m onth will be imputed as 
the 31stDecember of the y ear. 
7.2.5 Conventions for Missing Concomitant Medication Dates
Start and stop dates for all conco mitant medicat ions are collected on the CRF. However, in case 
of missing or partial informat ion in these dates, the fo llowing rul es will  be used:
If the start date i s missing or parti al:
-If the day  is missin g, the start day will be the first day  of the m onth
-If the month is missing, the start month will be the mo nth cor responding to [ADDRESS_810824] study  medicat ion date
-If the year i s miss ing, the start year will be the year of the entry  visit (or consent date, 
for those missing entry  visit)
-If the entire date is missing, the start date will be the date of first study  drug 
administration
If the stop date is missing, partial or ‚Äúcontinuing:‚Äù
-If the day  is missing, the stop day  will be the last day  of the m onth reported
-If the month is missing, the stop month will be the month during which the last dose 
of induct ion treatment was administered 
-If the year or the ent ire date i s missing or if th emedication is ‚Äúcont inuing‚Äù, the stop 
year will be the y ear in which the last dose of induction treatment was administered.
Vedolizumab -[ADDRESS_810825] Di sease will  be defined according to the 
modified Glucksberg criteria and Blood and Marrow Transplant Clinical Trials Network (BMT 
CTN)- modified Internat ional Bone Marrow Transplant Registry  Database (IBMTR) index (See
Appendix D).
The classificat ion the following rules apply :
1)For every  organ involvement ( skin, liver, or intestinal) i ftheGvHD invo lvement is 
marked as ‚ÄúYES‚Äù forthis organ involvement (skin, liver, or intestinal) on eCRF. andthe 
stage of this organ invo lvement is ‚â• 1, t he subjects should to be coun ted as having GvHD
involvement for this organ (skin, liver, or intestinal respectively ). 
2)If the invo lvement of an organ (Skin, Liver, or Intestinal) is marked as ‚ÄúYES ‚Äù but the 
stage of invo lvement is = 0, then the subject shou ld not be counted as having GvHD of 
that organ.
3)A subject should be counted as having overall GvHD if this subject has at least one organ 
involvement with stage ‚â•1. 
4)To assess the grade level for Liver GvHD invo lvement, t he maximal bilirubin level 
within the visit window shoul d be used (See Table 7.a).
7.3 Populations for Analys es
The fo llowing popul ations will be used for analysis:
ÔÄ≠Safety population: The populat ion of patients evaluable for vedo lizumab safet y is 
defined as all pat ients who receive any  amount of  vedo lizumab IV.
ÔÄ≠PK population: Defined as patients fro m the safety set with at least 1 PK sample 
collected. 
ÔÄ≠PD population: Defined as pat ients from the safety set with at least 1 PD sample 
collected.
For the primary  endpoint, an evaluable pat ient is one who receives vedo lizumab IV and is 
assessed for engraft ment on or before Day  +28.
Any additional analyses/sub -analyses for cohorts wil l be outlined in the CPAP , if deemed 
necessary .
7.[ADDRESS_810826] di sposi tion will include the fo llowing:
ÔÄ≠Study  Inform ation, including date first subject signed ICF, date of last subject‚Äôs last 
visit/contact, date of last subje ct‚Äôs l ast procedure for collect ion of data for primary  
endpo int.
Vedolizumab -1015 Page 19of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALÔÄ≠Summary  of Screen Failures. 
ÔÄ≠Number of subjects enro lled by [CONTACT_611480].
ÔÄ≠Number and percent of subjects complet ing 28 days
ÔÄ≠Number and percent of subjects complet ing 100 days
ÔÄ≠Number and percent of subjects complet ing 180 days
ÔÄ≠Number and percent of subjects complet ing 1 y ear
ÔÄ≠Number and percent of subjects receiving all 3 infusions
ÔÄ≠Number and percent of subjects receiving 2 infusio ns
ÔÄ≠Number and percent of subjects receiving 1 in fusio ns
ÔÄ≠Number and percent of subject receiving 0 infusio ns
ÔÄ≠Number of patients in the Safet y populati on.
ÔÄ≠Number of patients in the PK populat ion.
ÔÄ≠Number of patients in the PD populat ion.
ÔÄ≠Disposi tion of subjects based on the reasons for discontinuation o f treatment and for 
failing to complete the study .
ÔÄ≠Significant protocol  deviat ions, captured on the eCRF will be summarized descript ively.
7.[ADDRESS_810827] ics will be summarized by [CONTACT_611481] y analysis 
dataset (see Table 7.c).No baseline co mpar ison will be performed.
Categorical variables (including p rior treatm ent therapi [INVESTIGATOR_014])will be tabulated.  No baseline lab 
values will be tabulated. The number and pe rcentage of the observat ions for each category  will 
be reported .Categories that contain zero observations will be reported as ‚Äò0‚Äô, not omitted .
Missing and non -reported observat ion will  be reported as such, not omitted .
Continuous variables shoul d be summ arized for each dosing cohort using the following:
ÔÄ≠Number of observat ions (n),
ÔÄ≠Mean,
ÔÄ≠Standard deviat ion (SD),
ÔÄ≠Range of values ( Min, Max).
Vedolizumab -1015 Page 20of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALTable 7.c. Summary of Patients' Baseline and Demographic Characteri stics
Characteristic Summarized as Categories and measurement units
Age Continuous 18‚Äî 75 years
Age group Ordinal Categorical<35
>= 35 years
Gender Categorical Female/Male
Race CategoricalWhite/Black/Asian/Native American/ 
Asian Pacific/Other
Ethnici ty Categorical  Hispanic or Latino
  Not Hispanic or Latino
  Not Reported
Weight Continuous Kg
Height Continuous cm
Baseline ECOG Status Ordinal Categorical 0, 1, 2, 3, 4
Smoking status CategoricalCurrent Smoker
Never Smoked
Former Smoker
Underly ing disease diagnosis Categorical Myeloproliferative Neoplasm ,
   Myelodysplastic or Myelofroliferative 
Neoplasm ,
   Myelodysplastic syndrome ,
   Acute myeloid leukaemia or related 
precursor neoplasm ,
   Precursor lymphoid neoplasm ,
   Mature B -cell neoplas m,
   Mature T -cell and NK -cell neoplasm
Underly ing disease duration since 
diagnosisOrdinal Categorical and 
Continuous< 1 y ears 
‚â•1 ‚Äî<3 years 
‚â• 3 ‚Äî<7 years 
‚â•[ADDRESS_810828] Categorical Related/Not related
HLA Compatability Categorical Match/Mismatch
Cytomegalovirus IgG Antibody Catgo rical Positive/Negative
Source of stem cells Catgo rical Bone Marrow/ Peripheral Blood
Vedolizumab -1015 Page 21of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL7.6 Medication History and Concomitant Medications
During the Screening period, a complete medical history  will be com pi[INVESTIGATOR_53300]. The 
history  will emphasize the background and progress of the patient‚Äôs malignancy  and include a 
descript ion of prior t herapi[INVESTIGATOR_231910]. Medical and Surgical History will be summarized by  [CONTACT_414482].
In addit ion, concomita nt medicat ions used by  [CONTACT_611482] [ADDRESS_810829] igator(s). The appropriate study  personnel will maintain 
records of vedo lizumab receipt and di spensing .The numbe r of doses will be summarized as both 
continuous and ordinal categorical variable. 
Exposure to vedolizumab will be summarized and reasons for discont inuation will be tabulated 
by [CONTACT_15994] , as f ollowing:
ÔÉ∑ÔÉ∑
ÔÉ∏ÔÉ∂
ÔÉßÔÉß
ÔÉ®ÔÉ¶ÔÄΩ 1 ,Dose Total ExpectedDose Total ActualMin* 100 Com pliance %
7.8 Efficacy Analyse s
Efficac y endpo ints will be analyzed using the safety population.
7.8.1 Primary Efficacy Endpoint
{Not applicable}
7.8.2 Secondary Efficacy Endpoint s
Secondary  efficacy endpo ints are:
ÔÄ≠Time to neutrophil engraft ment (recovery  of ANC). The first day o f the 3-day period will 
be considered the day  of neutrophil engraft ment.
Vedolizumab-1015 Page 22 of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL!Percentage of patients who have developed overall Grade 2 to 4 acute GvHD (compi[INVESTIGATOR_611474], skin, or liv er) by [ADDRESS_810830].  
!The frequency of maximum severity of GvHD according to the modified Glucksberg 
criteria and BMT CTN-modified IBMTR index.
7.8.3 Explor atory Efficacy Endpoints
Exploratory efficacy endpoints are:
CCI
Vedolizumab -[ADDRESS_810831] oratory  analysis 
will be considered if confounding factors suspected.
Time -to-event (survival) endpo ints will be summarized for each dosing cohort and will display :
‚ÄìNumber and percent ageof events,
‚ÄìNumber and percent ageof censored observ ations,
‚ÄìMedian time to event and 95% CI,
‚Äì 25thpercentile o f the time to event and 95% CI,
‚Äì 75thpercentile o f the time to event and 95% CI,
‚ÄìRange (minimum and maximum time to event) ,
‚ÄìKaplan -Meier estimates of the event rates (percentage and n) at 6 m onths ,
‚ÄìKaplan -Meier estimates of the event rates (percentage and n) at 12 m onths,
‚Äì P lots of the Kaplan- Meier est imated survival curves.
The proporti on endpo ints (percentage of subjects meet ing endpo int criteria) will be summarized 
for each dosing cohort and will d isplay :
‚Äì N umber (n),
‚Äì P ercentage and 95% CI .
Frequency of maximum severit y of acute GvHD will  be summarized for each dosing cohort 
throughout the [ADDRESS_810832] and will display:
‚ÄìNumber ( n) of the acute GvHD cases for each severity category ,
‚ÄìPercentage and 95% CI for each severit y category ,
‚ÄìPlot of the frequencies for each acute GvHD severity  categories.
Unless otherwise noticed, a ll efficacy endpo ints that are defined using GvHD grading scale , will 
be summarized twice: based on the modified G lucksberg criteria ,and based on the IBMTR 
criteria, respectively. The appropriate grading scale should be explicit ly listed on all related 
summary tables, reports and figures, e.g. ‚ÄúGrade 2‚Äî 4 acute GvHD -free survival at 6 months 
(using modified Glucksberg criteria)‚Äù .
7.9 Pharmacokinetic/Pharmacodynamic Analysis
Concentrations of vedo lizumab will be summarized by [CONTACT_611483] t ime using 
descript ive statistics. Individual concentration -time profiles will be presented in data list ings.
Details o f the non- compartmental analysis (NCA) for the PK param eters will be provided in a 
Vedolizumab-1015 Page 24 of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALseparate Clinical Pharmacology Analysis Plan (CPAP) and the results of the analysis will be 
reported in the Clinical Study Report.
7.9.1 Pharmacokinetic Analysis
The PK analysis set will be used for all PK analyses. Treatment groups will be presented as 
defined in Section 7.2. Missing PK data will not be imputed. More details on the PK analysis 
will be described in a separate document, i.e., CPAP. 
Measured serum concentrations of vedolizumab will be summarized using descriptive statistics 
by [CONTACT_6982]/time separately. 
The mean serum concentration-time profile of ve dolizumab will be plotted by [CONTACT_115998]/or visit/time separately. Individual plot will be also presented.
The PK parameters (ex AUC, Cmax) will be summarized by [CONTACT_611484] (day -1, day +13 and day +[ADDRESS_810833]) separately using descriptive statistics 
(non-missing values, mean, SD, SE, %CV, geometric mean, geometric mean %CV, median, 
minimum and maximum) as appropriate. 
Serum concentration data and PK parameters will also be listed.
7.9.2 Pharmacodynamic Analysis
Summary of pharmacodynamics results and change from baseline will be summarized 
descriptively by [CONTACT_765].
7.9.3 Other Outcomes
Immunogenicity (anti-vedolizumab antibodies, AVA) will be descriptively summarized. The 
AVA status will be summarized descriptively, using AVA positive, AVA negative, and 
Neutralizing AVA positive subgroups. AVA positive subgroup will be summarized descriptively 
by [CONTACT_611485], persistently positi ve, and any neutralizing AVA positive subgroups. 
Summary of Anti-vedolizumab Antibody (AVA) Frequency will be summarized by [CONTACT_611486] (75mg and 300 mg).
The effect of anti-vedolizumab antibodies on PK (ex, exclude ADA positive patients), safety and 
efficacy will be explored.
AVA positive and negative sample will be defined as follows:
)Negative AVA: defined as a sample that is evaluated as negative in the AVA screening 
assay. Samples that are determined to be positive in the AVA screening assay but the 
result is not confirmed in the AVA confirmatory assay are considered negative.CCI
Vedolizumab -1015 Page 25of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALÔÇ∑Positive AVA: defined as a sample that was evaluated as posit ive in both the AVA 
screening and confirmatory  assays.
oTransient ly posit ive: defined as patients with confirmed positive AVA in 1sample.
oPersi stently posi tive: defined as pati ents wi th confirm ed posi tive AVA in 2 or more 
consecut ive posit ive AVA samples. 
ÔÇ∑Positive neutralizing AVA: defined as a sample that was evaluated as posit ive in the 
neutralizing AVA assay.
Patient AVA pos itive at baseline is defined as a posit ive AVA sample prior to Day  -1 dose.
7.10 Safety Analysis
For the primary  endpoint, an evaluable pat ient is one who receives vedo lizumab IV and is 
assessed for engraft ment on or before Day  +28. 
Safety will be evaluated by [CONTACT_51253], severit y and t ype of AEs, and by [CONTACT_4184] m 
baseline in the patient‚Äôs vital signs, weight, and clinical laboratory  resul ts using the safet y 
analysis set. Exposure to study  drug will  be summari zed and reasons for discont inuat ion wil l be 
tabul ated. Safet y will be summarized by [CONTACT_15994]. 
Hematology results, chemistry  resul ts, and urinalysis resul ts (including the appropriate changes 
from baseline )will be summarized by [CONTACT_53813].
Vita sign analysis and urine laboratory  tests will  besummarized by  [CONTACT_611487].
Shift s in laboratory  test resul ts for hem atology between l ow, normal  and high l evels will be 
summarized for each dose and the total by [CONTACT_154023].  
7.10.1 Adverse Events
Unless specified otherwise, the AEs will be tabulated according to MedDRA by [CONTACT_70244], high -level terms, and preferred terms and will include the fo llowing categories:
ÔÄ≠TEAEs.
ÔÄ≠Drug -related TEAEs.
ÔÄ≠Grade 3 or higher TEAEs.
ÔÄ≠Grade 3 or higher drug- related TEAEs.
ÔÄ≠The m ost comm only reported TEAEs (i .e., those events reported by  ‚â•10% of all pat ients)
by [CONTACT_73001] .
ÔÄ≠SAEs by [CONTACT_6657] .
ÔÄ≠Serious Drug -Related TEAE s by [CONTACT_103467].
Listings of PML checklist data and TEAEs resulting in study drug discont inuat ion will be 
provi ded.
Vedolizumab -[ADDRESS_810834] dose of study  
medicat ion.
7.10.2 Clinical Laboratory Evaluations
Descript ive statistics for the actual values of clinical laboratory parameters (and/or change from 
baseline in clinical laboratory  param eters) will be presented for all scheduled measurements over 
time. Mean laboratory  values over time will be plo tted for key laboratory parameters . Key 
param eters are: Liver funct ion tests (ALT, AST, Total Bilirubin, Alkaline phosphatase), WBC, 
Hem oglobin, Platel ets, Eos, Mono, Lymph, Neut, Basophils, calculated ANC . 
Shift tables for laboratory  parameters will be gene rated based on changes in NCI CTCAE grade 
from baseline to the worst postbaseline value. 
7.10.3 Vital Signs
Vital signs, including heart rate, respi[INVESTIGATOR_2842], systolic and diastolic blood pressure, and
temperature, will be recorded at the visit s specified in t he Schedule of Events ( Appendix B), and 
summarized using descript ive statist ics. On dosing day s, vital signs will  be obtained before the 
infusio n.Descript ive statistics for the actual values (and/or the change fro m baseline) of vital 
signs, wei ght, and bl ood pressure time will be tabulated by  [CONTACT_51256].
7.11 Interim Analysis
No interim analysis is planned. Toxicit ies will be continuously monitored during all phases of 
the study .
In addit ion to ongoing safet y reviews of cumulat ive data, early terminat ion of the study  will 
occur if any  of the f ollowing are observed during the expansion phase of the study :
ÔÄ≠3 cases of CMV colit is, or
ÔÄ≠3 cases of engraft ment failure; however, if first 2 cases of engraft ment failure are in 
patients who received myelo ablative condit ioning, the study  will be stopped.
7.12 Changes in the Statistical Analysis Plan 
Not applicable.
Vedolizumab -1015 Page 27of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIAL8.0 REFERENCES
[1] Rowlings PA, Przepi[INVESTIGATOR_12776] D, Klein JP, Gale RP, Passweg JR, Henslee -Downey  PJ, et al . 
IBMTR Severit yIndex for grading acute graft -versus -host disease: retrospective co mpar ison 
with Glucksberg grade. Br J Haematol 1997;97(4):855 -64.
Vedolizumab -1015 Page 28of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
9.0 APPENDIXES
Appendix A. Pharmacokinetic Sample Breakdown
Day
-1 0 +3 +5 +7 +9 +11 +13 +14 +16 +18 +20 +22 +26 +30 +36 +40 +42+100
(¬±7 days)
Serum
PK collection on non -dosing 
days (a)X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 X1 X1
Predose X1 X1 X1
30 min postdose ( ÔÇ±5 min) X1 X1 X1
1 hr postdose ( ÔÇ±10 min ) X1
2 hrs postdose ( ÔÇ±20 min) X1 X1 X1
12 hrs postdose ( ÔÇ±30 min) X1 X1
24 hrs postdose ( ÔÇ±60 min) X1 X1
(a) Once the patient completes the inpatient period (as determined by [CONTACT_8647]), sample collection may be aligned with clinic visits. All PK samples should be 
collected within 10% of nominal time; however, samples collected outside this margin will not be considered protocol deviatio ns. The total number of collected PK 
sample s should be no greater than the amount outlined in this table.
Vedolizumab -1015 Page 29of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALAppendix B. Schedule of Events (Screening through Day +20)
Screening 
(a)Day 
‚Äì1Day 
0Day 
+1Day 
+3Day 
+5Day 
+7Day 
+9Day 
+11Day 
+13Day 
+14Day 
+16Day 
+18Day 
+20
Informed consent X
Inclusion/exclusion criteria X X(b)
Demographics X
Medical history X X(c)
Complete physical examination and 
neurological assessmentX
Symptom -directed physica l 
examinationX X X X
Height X
Weight X X X X
Vital signs X X(b) X X (b) X
ECOG performance status X
HCT-CI (dose -finding phase only)
Tuberculosis screening X(d)
RAM P questionnaire X X(b) X (b)
Monitoring of concomitant medications 
and proceduresRecorded from first dose of study drug through [ADDRESS_810835] dose of study drug
Serious adverse events (e) will be reported from signing of the informed consent form through [ADDRESS_810836] dose of study drug.
Vedolizumab IV administration(f) X X
Allo-HSCT (g) X
Samples/Laboratory Assessments
Pregnancy test (h) X1 X1
Hematology/chemistry X1 X1(b) X1 X1 (b) X1
Urinalysis X1 X1(b)
Blood sample for flow cytometry (i,j,k) X1(b) X1 X1 X1 (b) X1
Blood sample for serum biomarkers (j,l) X1(b) X1 X1 X1 (b) X1
Blood sample for anti -vedolizumab 
antibodies (j)X1(b) X1
Vedolizumab -[ADDRESS_810837]=allogeneic hematopoietic stem cell transplantation, ECOG= Eastern Cooperative Oncology Group, GvHD=graft -verus -host dis ease, HCT -
CI=Hematopoietic Cell Transplantation -Specific Comorbidity Index, ICF=informed consent form, IV=intravenous, PK=pharmacokinetic(s), RAMP= 
Risk Assessment and Minimization for Progressive Multifocal Leukoencephalopathy (PML).
(a) Unless otherwise noted, the Screening visit must occur within [ADDRESS_810838] dose of study drug (Day ‚Äì1); however, the ICF may 
be signed more than 28 days prior to Day ‚Äì1.
(b) Assessment/sample collection should be performed predose.
(c) The Day ‚Äì[ADDRESS_810839] d ose of 
study drug (Day ‚Äì1).
(d) QuantiFERON¬Ætest or tuberculin skin test only. 
(e) Including serious pretreatment events .
(f) Ved olizumab will be administered via a 30 -minute intravenous (IV) infusion on Day ‚Äì1. HSC infusion should occur on Day 0 no sooner than 12 
hours after completion of IV infusion of vedolizumab on Day ‚Äì1. Vedolizumab will also be administered via a 30 -minute IV infusion on Day +[ADDRESS_810840].
(g) Details on the HSC infusion including cell counts and donor CMV status will be recorded on the eCRF.
(h) A serum beta -human chorionic gonadotropin ( ÔÅ¢-hCG) pregnancy test will be performed only for pat ients of childbearing potential during screening 
and again on Day ‚Äì1 (baseline) if the screening test was performed more than [ADDRESS_810841] of an IEC/IRB, or if required by [CONTACT_427].
(i) Additional specimens may be collected from any patient who experiences an infusion reaction.
(j) An additional sample may be collected from any patient who develops Gv HD. 
(k) Includes immunophenotypi[INVESTIGATOR_611475] -1 (immunophenotypi[INVESTIGATOR_611476]).
(l) To be collected 24 hours (ÔÇ± 3 hours) postdose from the preceding day.
(m) Time points for blood samples for PK analysis will be collected as specifie d inAppendix A.
Vedolizumab -1015 Page 31of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALAppendix C. Schedule of Events (Day +22 t hrough end of study)
Day 
+22Day 
+26Day 
+30Day 
+34Day 
+36Day 
+40Day 
+42Day 
+100 
Visit 
(a)4 month 
Follow -up 
Visit (b)5 month 
Follow -up 
Visit (b)6 month 
Follow -up 
Visit (b)9 month 
Follow -up 
Visit (b)12 month 
Follow -
up/EOS/ET 
Visit (b)OS 
Follow -
up
Symptom -directed physical 
examinationX X X X X X X X X
Weight X X X X X X X X X
Vital signs X X X (c) X X X X X X
RAMP questionnaire X (c)
Follow -up phone calls Q3mo 
(d)
Assessment of GvHD X X X X X X X X X
Monitoring of concomitant 
medications and proceduresRecorded from first dose of study drug through [ADDRESS_810842] dose of study drug
Serious adverse events (e) will be reported from signing of the informed consent form through [ADDRESS_810843] dose of study drug.
Vedolizumab IV administration (f) X
Samples/Laboratory Assessments
Hematology/chemistry (g) X1 X1 X1 
(c)X1 X1 X1 X1 X1 X1
Urinalysis
Blood sample for chimerism 
analysisX1
Blood sample for flow cytometry (h) X1 X1 X1 
(c)X1 X1
Blood sample for serum biomarkers 
(i)X1 X1X1 
(c)X1
Blood sample for anti -vedolizumab 
antibodies (h)X1 X1
Blood sample for PK (j) See Appendix A.Error! Reference source not found.
Vedolizumab -1015 Page 32of 34
Statistical Analysis Plan Final Version 1.0 June 04, 2018
CONFIDENTIALComplete remission with incomplete platelet recover y=CRp, EOS=end -of-study, ET=early termination, GvHD=graft -verus -host disease, 
IV=intravenous, OS=overall survival, PK=pharmacokinetic(s), World Health Organization=WHO.
(a) Patients will attend a Day +100 visit (¬±7 days) at which time patients will enter posttreatment follow -up. If subsequent anticancer therapy is required 
before [ADDRESS_810844] dose, the Day + 100 visit should be conducted before the initiation of subsequent anticancer therapy.
(b) Patients who remain in remission will be followed for development of acute and chronic GvHD and safety during clinic visi ts at 4, 5, 6, 9, and [ADDRESS_810845] or until the patient‚Äôs death or withdrawal of consent or termination of the study by [CONTACT_456]. Patients who complete th e study 
will attend a 12- month follow -up visit (EOS). Patients who have been discontinued will attend an ET visit [ADDRESS_810846] dose of study drug 
using all study procedures outlined for the 12 -month follow -up visit.
(c) Assessment/sample collection should be performed pre -dose.
(d) Patients will be followed for overall survival ever y [ADDRESS_810847] patient is enrolled in the study. OS is defined as the time f rom the date of enrollment to 
the date of death. 
(e) Including serious pretreatment events; see Section 11.2.
(f) If engraftment is confirmed, vedolizumab will be administered via a 30 -minute intravenous (IV) infusion on Day +[ADDRESS_810848].
(g) Hepatitis and HIV testing are to be performed only at the Scre ening visit.
(h) Additional specimens may be collected from any patient who experiences an infusion reaction.
(i) An additional sample may be collected from any patient who develops GvHD.
(j) Time points for blood samples for PK analysis will be collected as specified in Appendix A.
Note: Tests and procedures should be performed on schedule, but occasional changes are allowable (¬± 2 days, except where othe rwise specified) with 
permission of the medical monitor for h olidays, vacations, and other administrative reasons. If extenuating circumstances prevent a patient from 
beginning treatment or completing a scheduled procedure or assessment within this time, the patient may continue the study on ly with the written 
permi ssion of the medical monitor.
Vedolizumab -[ADDRESS_810849] Disease Grade (modified Glucksberg)
Grade Skin Liver Intestinal tract
I Stage 1 -2and ÔÉ† None and ÔÉ† None
II Stage 3 or ÔÉ† Stage 1 or ÔÉ† Stage 1
III - Stage 2 -3 or ÔÉ† Stage 2 -4
IV Stage 4 or ÔÉ† Stage [ADDRESS_810850]
Stage 
(max) Extent of RashStage 
(max)Total B ilirubin 
(Œºmol/L)Stage 
(max) Volume of Diarrhea (mL/day)
A 1 <25% and 0 <34 and 0 <500
B 2 25-50% or 1-2 34-102 or 1-2 550-1500
C 3 >50% or 3 103-255 or 3 >1500
D 4 Bullae or 4 >255 or 4 Severe pain and ileus
From Rowlings et al., 199 7.[1]
Vedolizumab -[ADDRESS_810851] of GvHD.

 ‰¢¢
‰¢¢‰¢¢‰¢¢
‰¢¢
‰¢¢‰¢¢
‰¢¢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‚ÄòUTC‚Äô) 

  

  

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   



GDDEF‰£ò‰£ß‰£¶‰£±‰£Æ‰£´‰£º‰£∑‰£Ø‰££‰£§‰¢Ø‰¢≥‰¢≤‰¢≥‰¢∑‰¢¢‰£ï‰£∂‰££‰£∂‰£´‰£µ‰£∂‰£´‰£•‰££‰£Æ‰¢¢‰£É‰£∞‰££‰£Æ‰£ª‰£µ‰£´‰£µ‰¢¢‰£í‰£Æ‰££‰£∞‰¢¢‰¢¥‰¢≤‰¢≥‰¢∫‰¢Ø‰¢≤‰¢∑‰¢Ø‰¢¥‰¢∂
%LRVWDWLVWLFV$SSURYDO -XQ87&
%LRVWDWLVWLFV$SSURYDO -XQ87&
&OLQLFDO6FLHQFH$SSURYDO -XQ87&
&OLQLFDO3KDUPDFRORJ\$SSURYDO -XQ87&
3KDUPDFRYLJLODQFH$SSURYDO -XQ87&[COMPANY_003]